Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT04649411
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04523727
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of California, San Francisco (UCSF) - Department of Nephrology, San Francisco, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT03236246
- Locations
- 🇺🇸
Miami Kidney Group, Miami, Florida, United States
🇺🇸Renal Associates, LLC, Columbus, Georgia, United States
🇺🇸Hypertension and Nephrology Association, Eatontown, New Jersey, United States
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT02268994
- Locations
- 🇺🇸
California Renal Research, Glendale, California, United States
🇺🇸Academic Medical Research Institute, Inc, Los Angeles, California, United States
🇺🇸Kidney Care Associates, LLC, Augusta, Georgia, United States
A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02128074
- Locations
- 🇮🇱
Western Galilee Hospital, Nahariya, Israel
🇮🇱Barzilai Medical Center, Ashkelon, Israel
🇮🇱Nazareth Hospital- EMMS, Nazareth, Israel
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT01736397
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT01554982
- Locations
- 🇺🇸
Kidney Care Associates, LLC, Augusta, Georgia, United States
🇺🇸Asheville Kidney Center, Asheville, North Carolina, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 441
- Registration Number
- NCT01191255
- Locations
- 🇺🇸
Circle Medical Management, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Foundation Q7-150 Nephrology, Cleveland, Ohio, United States
🇺🇸Nephrology, PA, Houston, Texas, United States
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT01074125
- Locations
- 🇺🇸
Centre Point Dialysis, West Allis, Wisconsin, United States
🇺🇸Western Nephrology, Westminster, Colorado, United States
🇺🇸Pines Clinical Research, Inc., Pembroke Pines, Florida, United States
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Keryx Biopharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00967993
- Locations
- 🇮🇱
Barzilai Medical Center Ben-Gurion University, Ashkelon, Israel
🇮🇱Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
🇮🇱Assaf Haraofeh Medical Center, Zerifin, Israel